FindMyKOL

Todd Shenkenberg, MD

Basic profile

Hematology / Oncology

ORCIDNone on fileNPIOn fileSign in to see identifiers
✓ Itemized record
RegionHarlingen, TX · South CentralSpecialtyHematology / OncologyFocusOncology
Active KOLFindMyKOL type: RegionalLatest publicationSee ScholarshipOnline presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Todd Shenkenberg is an Oncology physician. OpenAlex indexes 14 publications with 417 citations (h-index 8).

Overview

Scholarship

indexed output and impact (OpenAlex)
14publications

Publications indexed by OpenAlex. Counts exclude supporting files.

417citations

Citations across these publications.

8h-index

H-index from these publications.

Clinical & industry

trials, payments and federal funding
98companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓

Industry payments

98 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

  • Pfizer
    Program year20251 paymentResearch
    $3,400
  • Janssen Biotech, Inc.
    Program year202511 payments
    $338
  • PFIZER INC.
    Program year202514 payments
    $252
All 245 payment records: search, sort and filter.Explore →

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward. Research funding is listed under each investigator the record names.

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Blood & clotting

    48.7%
    Parenteral Iron Replacement44.9%
    Iron sucrose100%
    Part B, office-administered≥42 patients
    Erythropoiesis-stimulating Agent3.3%
    Epoetin alfa100%
    Part B, office-administered≥18 patients

    + 5 more classes in this area

  • Cancer & immunology

    17.4%
    PD-1 inhibitor15.4%
    Pembrolizumab100%
    Part B, office-administered≥13 patients
    Aromatase Inhibitor0.8%
    Letrozole62%Anastrozole32%Exemestane5%Femara2%
    Part D<11 patients

    + 15 more classes in this area

  • Musculoskeletal

    14.5%
    RANK Ligand Inhibitor13.6%
    Denosumab100%Xgeva0%
    Part D + Part B<11 patients
    Cyclooxygenase Inhibitor0.3%
    Ketorolac tromethamine100%
    Part B, office-administered≥40 patients

    + 6 more classes in this area

Where care is delivered (Part B)0.9% facility · 99.1% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”